The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Evaluating 3 Types of Targeted Therapies for Triple-Negative Breast Cancer

Aditya Bardia, MBBS, MPH
Published Online:1:39 PM, Mon March 18, 2019


Aditya Bardia, MBBS, MPH, a breast medical oncologist at Massachusetts General Hospital and Harvard Medical School, discusses the development of targeted therapies for patients with triple-negative breast cancer (TNBC). He says these approaches can be divided into 3 different categories.

The first category would be targeting oncogenes. An example of this would be the use of PARP inhibitors. Second, ongoing trials are also looking at intercellular signaling pathways, says Bardia.

The third category of targeted therapies being developed in TNBC is antibody-drug conjugates. As in the other categories, the role of these agents is being explored for the treatment of patients with TNBC, Bardia concludes.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.